Measuring Healthy Aging with the Intrinsic Capacity (IC) Clock: A Functional Aging Breakthrough

Aging is more than the passage of time; it is marked by a progressive decline in the physiological and psychological reserves that sustain independence and well-being.  A recent article published in Nature Aging ⁽¹⁾ by researchers from the IHU HealthAge (France) and the Buck Institute for Research on Aging (US) introduces a significant advancement in measuring healthy aging. Drawing on data from 1,014 individuals aged 20 to 102, the team developed the Intrinsic Capacity (IC) clock, a DNA methylation-based tool trained on five key domains: cognition, locomotion, psychological well-being, sensory abilities, and vitality. The IC clock outperformed earlier epigenetic clocks in predicting all-cause mortality and showed strong associations with molecular biomarkers, clinical outcomes, and lifestyle factors. These findings position the IC clock as a powerful link between biological aging markers and real-world functional health.

Defining and Quantifying Intrinsic Capacity

What is intrinsic capacity (IC)?

Intrinsic Capacity (IC) is a concept introduced by the World Health Organization (WHO) in 2015, defined as the composite of all physical and mental capacities that an individual can utilize at any point in their life.  Unlike traditional health measures focused on disease, IC emphasizes functional ability and marks a shift toward promoting healthy aging. Recognized globally, IC is now coded in ICD-11 (MG2A10) as “aging-associated decline in IC.” Researchers have developed IC scores to quantify this capacity, linking it to outcomes like frailty, comorbidities, falls, and daily function.

Quantifying Intrinsic Capacity Across the Lifespan

In the current study published in Nature Aging, IC scores range from 0 (worst) to 1 (best), and were derived from standardized clinical assessments within the INSPIRE-T (Integrated cohort for the Study of Intrinsic Capacity and Healthy Aging, Translational) cohort (n=1,014; aged 20–102 years), a large, longitudinal research cohort designed to investigate the biological and functional changes associated with aging across the adult lifespan. It includes over 1,000 participants aged 20 to 102 years and focuses on evaluating Intrinsic Capacity (IC), a measure of physical and mental function, alongside molecular and clinical biomarkers.  Age-related decline was observed across all five domains, with the strongest correlation seen for overall IC (Spearman’s rs = –0.65). Interestingly, psychological well-being exhibited the weakest age correlation. Sex-specific patterns also emerged: males scored higher in vitality and psychological domains, whereas females outperformed in sensory function. Notably, sensory decline began earlier in females (42 years vs. 67 in males), while cognitive decline occurred earlier in males (72 vs. 86 years). These findings reinforce IC as an integrative and nuanced metric of functional aging, modulated by both biological and demographic factors.

Building the IC Clock: A Novel Epigenetic Biomarker

To construct the IC clock, researchers utilized DNA methylation (DNAm) data from 933 INSPIRE-T participants and applied elastic net regression with tenfold cross-validation. The resulting model, based on 91 CpG sites, achieved a robust correlation between predicted and observed IC scores (rs = 0.61). Importantly, while DNAm IC was highly correlated with chronological age (rs = –0.92), the top predictive CpGs showed little to no correlation with age, indicating that the IC clock captures distinct aging biology, rather than merely tracking time.

Development and Validation of the IC Clock

Using data from 933 participants aged 20 to 102 years in the INSPIRE-T cohort, researchers developed an Intrinsic Capacity (IC) score encompassing five key domains: cognition (assessed by the Mini-Mental State Examination), locomotion (Short Physical Performance Battery), psychological well-being (PHQ-9 depression scale), sensory function (vision and hearing tests), and vitality (measured by handgrip strength). These scores were normalized on a 0 to 1 scale, with higher scores indicating better function. The overall IC score showed a strong negative correlation with chronological age (Spearman’s ρ = –0.65, P = 9.97 × 10⁻¹¹¹). Sex-based differences were observed, with females exhibiting earlier sensory decline (age 42 vs. 67 in males), and males showing earlier cognitive decline (age 72 vs. 86 in females).

To develop a DNA methylation-based predictor of IC, methylation data were analyzed using elastic net regression with tenfold cross-validation. The best-performing model, using an alpha value of 0.9, included 91 CpG sites and predicted IC with high accuracy (ρ = 0.61 compared to clinically derived IC scores). Notably, the predictive CpGs had minimal correlation with chronological age, suggesting that the IC clock reflects unique biological features rather than merely tracking age.

Validation in the Framingham Heart Study (FHS) supported these findings. IC estimates derived from saliva showed strong concordance with blood-derived measures (ρ = 0.64, P = 1.23 × 10⁻⁴), demonstrating the feasibility of non-invasive sampling.

The IC Clock Links Functional Aging to Immune and Inflammatory Profiles

The IC clock showed strong associations with immune system aging and inflammation. Analysis of age-adjusted DNA methylation IC scores revealed significant correlations with 578 genes, including CD28, a key T-cell costimulatory molecule essential for immune function, which was the most upregulated gene. In contrast, CDK14/PFTK1, a gene associated with inflammation and neurodegeneration, was notably downregulated. In terms of immune cell composition, higher DNAm IC scores were linked to greater levels of CD4⁺ T cells (  and naive CD8⁺ T cells, alongside reduced numbers of exhausted CD8⁺ T cells. Furthermore, pathway enrichment analysis showed that IC-associated genes were significantly enriched for processes related to T-cell activation, cellular senescence, and chronic inflammation. Together, these results highlight the IC clock’s ability to detect features of immunosenescence, providing a molecular link between functional decline and immune aging.

Molecular Mapping of Intrinsic Capacity Domains Reveals Distinct Aging Mechanisms

Each domain of Intrinsic Capacity (IC) was associated with distinct molecular pathways, highlighting the biological specificity underlying different aspects of functional aging. The vitality domain showed upregulation of mitochondrial electron transport genes, indicating a link to energy metabolism and mitochondrial health. Locomotion was associated with enhanced cardiac muscle adaptation and activation of Notch signaling pathways, both critical for muscle maintenance and regeneration. In contrast, cognition was characterized by reduced expression of genes involved in neuronal development, reflecting potential declines in neuroplasticity. The psychological domain showed significant downregulation of DNA repair mechanisms, suggesting increased genomic instability. Finally, the sensory domain revealed upregulated ribosome biogenesis and downregulated immune responses, indicating altered protein synthesis and immune modulation. These findings support the potential for domain-specific interventions targeting the biological hallmarks most relevant to each functional area of aging.

Epigenetic Signatures of Intrinsic Capacity Forecast Mortality and Functional Decline

The IC clock demonstrated strong predictive power for mortality, despite not being trained on survival outcomes. For all-cause mortality, each standard deviation increase in DNAm IC age acceleration was associated with a hazard ratio , outperforming both PhenoAge and GrimAge. In cause-specific analyses, the IC clock significantly predicted death from cardiovascular disease, heart failure, and stroke or transient ischemic attack. Individuals with high DNAm IC exhibited a 5.5-year survival advantage compared to those with low DNAm IC. Clinically, higher DNAm IC scores were linked to better physical health indicators, including superior pulmonary function, faster gait speed, greater bone mineral density, and more favorable self-reported health. Additionally, high DNAm IC was associated with lower levels of inflammatory markers such as C-reactive protein (CRP) and interleukin-6 (IL-6), as well as reduced tau protein levels and lower smoking exposure. These findings underscore the IC clock’s utility as a comprehensive biomarker of functional health and longevity.

Modifiable Dietary Factors Influence Epigenetic Markers of Functional Aging

The study identified several dietary factors that significantly modulate DNA methylation-based Intrinsic Capacity (DNAm IC). Higher IC scores were positively associated with consumption of dark meat fish such as mackerel and salmon, and with elevated levels of blood omega-3 fatty acids, particularly DHA. Interestingly, moderate beer consumption also correlated positively with IC. On the other hand, the use of calcium supplements was negatively associated with DNAm IC. Additionally, maintaining sugar intake within recommended levels (approximately 55% of total energy) was linked to higher IC scores. These findings suggest that targeted dietary strategies, especially those involving omega-3-rich fish and balanced macronutrient intake, may play a beneficial role in preserving functional health and mitigating age-related decline in IC.

IC Clock Outperformed Both First-Generation And Second-Generation Epigenetic Clocks

Epigenetic clocks estimate biological age by analyzing DNA methylation at CpG sites. They fall into two categories: first-generation clocks estimate chronological age, while second-generation clocks assess biological age and health span (Table 1). The table below summarizes the characteristics of key epigenetic clocks, including the newly developed IC Clock.

In the Framingham Heart Study (FHS), the IC Clock was compared to established epigenetic clocks to assess its ability to predict mortality. The DNA methylation-based Intrinsic Capacity (DNAm IC) clock demonstrated the highest predictive power for all-cause mortality, with a hazard ratio (HR) of 1.38 and a highly significant P-value of 1.67 × 10⁻²⁴. This outperformed the second-generation clocks PhenoAge (HR = 1.33) and GrimAge (HR = 1.29), as well as the first-generation clocks Horvath (HR = 1.21) and Hannum (HR = 1.15). Notably, despite not being trained on mortality outcomes, the IC Clock more effectively identified individuals at elevated risk of death. Its superior performance likely stems from its foundation in functional health rather than chronological age or disease-specific biomarkers. Furthermore, it showed strong associations with clinical outcomes, immune system markers, and lifestyle factors, positioning it as a robust systems-level biomarker of biological and functional aging.

Table 1: Comparison of intrinsic clock (IC) with first-Generation and second-generation epigenetic clocks.

The IC Clock: A Transformative Biomarker for Functional Aging

The IC clock represents a major advancement in aging biomarkers by converting complex assessments of Intrinsic Capacity (IC) into a simple, objective test using blood or saliva, enabling large-scale monitoring of functional aging. It captures key biological processes such as CD28 loss and immunosenescence, suggesting immune rejuvenation as a therapeutic target. Its domain-specific molecular signatures provide direction for personalized interventions, such as mitochondrial support for vitality. Additionally, lifestyle factors like marine omega-3 intake and moderate sugar consumption are linked to higher IC, reinforcing its role in preventive health strategies.

While powerful, the IC clock has limitations, including underrepresentation of individuals over 90 and unresolved causal links between immune markers and IC—particularly in the context of cytomegalovirus. Future work should focus on validating the clock in diverse populations and evaluating its response to targeted therapies.

More than a predictor of mortality, the IC clock functions as a systems-level biomarker, integrating immune, inflammatory, and lifestyle influences into a unified measure of functional aging. By quantifying the biological basis of IC, it offers a roadmap for extending health span. As the WHO recognizes IC decline in ICD-11 (MG2A), this tool has the potential to transform geriatric care—from treating disease to maintaining functional resilience across the lifespan.

References

1. A blood-based epigenetic clock for intrinsic capacity predicts mortality and is associated with clinical, immunological and lifestyle factors. Nat Aging5, 1207–1216 (2025). https://doi.org/10.1038/s43587-025-00883-5
2. Epigenetic Clocks: In Aging-Related and Complex Diseases. Cytogenet Genome Res (2023) 163 (5-6): 247–256. https://doi.org/10.1159/000534561
3. GrimAge Outperforms Other Epigenetic Clocks in the Prediction of Age-Related Clinical Phenotypes and All-Cause MortalityJ Gerontol A Biol Sci Med Sci. 2020 Nov 19;76(5):741–749. doi: 1093/gerona/glaa286

Disclaimer: This blog post is intended solely for educational and scientific informational purposes. Any mention of therapeutic drug names, including FDA-approved medications, is for the purpose of accurate reporting and discussion of biomedical research and does not constitute medical advice, endorsement, or promotion. Readers should not interpret the content as a recommendation for any specific treatment. Always consult a qualified healthcare professional for medical advice or treatment decisions.

About Marin Biologic Laboratories

Our Recent Publication/Meeting Presentation on Gene Therapy

1.  Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
bioRxiv 2025.03.19.644217; doi: https://doi.org/10.1101/2025.03.19.644217
2. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. bioRxiv 2025.04.15.648836v1 https://www.biorxiv.org/content/10.1101/2025.04.15.648836v1
3.  American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity  Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise

With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.

Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.

Download the full presentation: Development of Custom Cell Based and In vitro Potency and Pharmacokinetics (PK) Assays for AAV vectors- Marin biologic Laboratories

Development of Cell-Based Potency Assays: Case Studies and Blogs from Marin Biologic Laboratories (MarinBio)

Drug Discovery & Development Assays Offered by Marin Biologic Laboratories (MarinBio)

• ADME/Tox
• Molecular Biology
• The Art of Cell Culture
• Exosomes
• Stability Services
• Potency Assay
• Gene Therapy Assays
• Immunotherapy Assays
• Antiviral Therapy Assays
• cGMP
• MLR
• Cell Based Assays
• ELISA
• Flow Cytometry
• Protein
• PCR-qPCR
• Immunoassay
• Radioimmunoassay
• GLP
• Transfection
• Cell Therapy Assays
• Targeted Protein Degradation
• Research to Commercialization